Glenmark Life Sciences Share Price
Start SIP in Glenmark Life Sciences
Start SIPGlenmark Life Sciences Performance
Day Range
- Low 1,275
- High 1,326
52 Week Range
- Low 611
- High 1,335
- Open Price1,311
- Previous Close1,311
- Volume214777
Glenmark Life Sciences Investment Rating
-
Master Rating:
-
Glenmark Life Sciences has an operating revenue of Rs. 2,293.38 Cr. on a trailing 12-month basis. An annual revenue growth of 5% is not great, Pre-tax margin of 28% is great, ROE of 20% is exceptional. The company is debt free and has a strong balance sheet enabling it to report stable earnings growth across business cycles. The stock from a technical standpoint is comfortably placed above its key moving averages, around 32% and 56% from 50DMA and 200DMA. From an O'Neil Methodology perspective, the stock has an EPS Rank of 45 which is a POOR score indicating inconsistency in earnings, a RS Rating of 85 which is GOOD indicating the outperformance as compared to other stocks, Buyer Demand at A+ which is evident from recent demand for the stock, Group Rank of 13 indicates it belongs to a strong industry group of Medical-Ethical Drugs and a Master Score of B is close to being the best. Institutional holding has remained stable in the last reported quarter. Overall, the stock is lagging behind in earnings parameter, but excellent technical strength makes it a stock to examine in more detail.
EPS Strength
Price Strength
Buyer Demand
Group Rank
| Indicator | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 |
|---|---|---|---|---|---|---|
| Oper Rev Qtr Cr | 589 | 537 | 573 | 595 | 578 | 621 |
| Operating Expenses Qtr Cr | 429 | 395 | 400 | 428 | 385 | 415 |
| Operating Profit Qtr Cr | 159 | 141 | 173 | 167 | 193 | 206 |
| Depreciation Qtr Cr | 14 | 15 | 13 | 13 | 13 | 12 |
| Interest Qtr Cr | 0 | 0 | 0 | 0 | 0 | 0 |
| Tax Qtr Cr | 39 | 32 | 42 | 40 | 47 | 51 |
| Net Profit Qtr Cr | 111 | 98 | 119 | 119 | 135 | 146 |
Glenmark Life Sciences Technicals
EMA & SMA
- Bullish Moving Average
- ___
- 16
- Bearish Moving Average
- ___
- 0
- 20 Day
- ₹1,160.62
- 50 Day
- ₹1,040.43
- 100 Day
- ₹953.21
- 200 Day
- ₹858.76
- 20 Day
- ₹1,134.49
- 50 Day
- ₹993.83
- 100 Day
- ₹917.70
- 200 Day
- ₹841.89
Glenmark Life Sciences Resistance and Support
| Resistance | |
|---|---|
| First Resistance | 1,333.00 |
| Second Resistance | 1,355.45 |
| Third Resistance | 1,384.45 |
| RSI | 82.25 |
| MFI | 98.63 |
| MACD Single Line | 75.86 |
| MACD | 93.79 |
| Support | |
|---|---|
| First Support | 1,281.55 |
| Second Support | 1,252.55 |
| Third Supoort | 1,230.10 |
Glenmark Life Sciences Delivery and Volume
| Period | NSE + BSE Volume Avg | NSE + BSE Delivery Volume Avg | NSE + BSE Delivery Volume % |
|---|---|---|---|
| Day | 223,360 | 8,016,390 | 35.89 |
| Week | 409,343 | 12,190,235 | 29.78 |
| 1 Month | 426,641 | 13,123,491 | 30.76 |
| 6 Month | 224,497 | 9,985,618 | 44.48 |
Glenmark Life Sciences Result Highlights
Glenmark Life Sciences Synopsis
NSE-Medical-Ethical Drugs
Glenmark Life Scienc is involved in the business activities of Manufacture of medicinal substances used in the manufacture of pharmaceuticals: antibiotics, endocrine products, basic vitamins; opium derivatives; sulpha drugs; serums and plasmas; salicylic acid, its salts and esters; glycosides and vegetable alkaloids; chemically pure suger etc.. Company’s Total Operating Revenue is Rs. 2283.21 Cr. and Equity Capital is Rs. 24.51 Cr. for the Year ended 31/03/2024. Glenmark Life Sciences Ltd. is a Public Limited Listed company incorporated on 23/06/2011 and has its registered office in the State of Maharashtra, India. Company’s Corporate Identification Number(CIN) is L74900PN2011PLC139963 and registration number is 139963.| Market Cap | 16,062 |
| Sales | 2,293 |
| Shares in Float | 2.08 |
| No of funds | 88 |
| Yield | 1.72 |
| Book Value | 6.89 |
| U/D Vol ratio | 3.3 |
| LTDebt / Equity | |
| Alpha | 0.27 |
| Beta | 0.35 |
Glenmark Life Sciences Shareholding Pattern
| Owner Name | Jun-24 | Mar-24 | Dec-23 | Sep-23 |
|---|---|---|---|---|
| Promoters | 82.85% | 82.85% | 82.85% | 82.85% |
| Mutual Funds | 1.01% | 0.93% | 0.59% | 0.38% |
| Insurance Companies | 0.15% | |||
| Foreign Portfolio Investors | 4.81% | 5.01% | 4.57% | 4.39% |
| Financial Institutions/ Banks | ||||
| Individual Investors | 9.13% | 9.09% | 9.2% | 9.21% |
| Others | 2.2% | 2.12% | 2.79% | 3.02% |
Glenmark Life Sciences Management
| Name | Designation |
|---|---|
| Mr. Glenn Saldanha | Chairman & Non-Exe.Director |
| Dr. Yasir Rawjee | Managing Director & CEO |
| Mr. Vinod Naik | Executive Director |
| Mr. V S Mani | Non Executive Director |
| Mr. Sridhar Gorthi | Independent Director |
| Mrs. Manju Agarwal | Independent Director |
| Mr. Taruvai Laxminarayanan Easwar | Independent Director |
| Ms. Gita Nayyar | Independent Director |
Glenmark Life Sciences Forecast
Price Estimates
Glenmark Life Sciences Corporate Action
| Date | Purpose | Remarks |
|---|---|---|
| 2024-07-25 | Quarterly Results | |
| 2024-04-25 | Audited Results | |
| 2024-01-23 | Quarterly Results | |
| 2023-10-20 | Quarterly Results | |
| 2023-10-09 | Interim Dividend |
| Date | Purpose | Remarks |
|---|---|---|
| 2023-10-17 | INTERIM | Rs.22.50 per share(1125%)Interim Dividend |
| 2023-03-24 | INTERIM | Rs.21.00 per share(1050%)Interim Dividend |
| 2021-11-23 | INTERIM | Rs.10.50 per share(525%)Interim Dividend |
Glenmark Life Sciences FAQs
What is Share Price of Glenmark Life Sciences ?
Glenmark Life Sciences share price is ₹1,310 As on 18 September, 2024 | 02:28
What is the Market Cap of Glenmark Life Sciences ?
The Market Cap of Glenmark Life Sciences is ₹16058 Cr As on 18 September, 2024 | 02:28
What is the P/E ratio of Glenmark Life Sciences ?
The P/E ratio of Glenmark Life Sciences is 35.9 As on 18 September, 2024 | 02:28
What is the PB ratio of Glenmark Life Sciences ?
The PB ratio of Glenmark Life Sciences is 6.9 As on 18 September, 2024 | 02:28